Rare diseases
Investigational molecules
Locations
Arnold-Heller-Strasse 3, Brunswik, 24105 Kiel, Germany
Research activity includes multiple myeloma and acute lymphoblastic leukemia in children and adolescents, with interest in treatment response, disease control, and risk-adapted therapy.
The sponsor also supports work in treatment stratification and maintenance of remission in blood cancers.
Universitaetsklinikum Schleswig-Holstein AöR runs clinical trials in conditions such as Colitis ulcerative, Acute lymphocytic leukaemia, Crohn's disease, Glucose tolerance impaired, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Study of mirikizumab versus azathioprine in newly diagnosed moderate-to-severe Crohn’s disease patients
GermanyEvaluation of controlled-ileal-release nicotinic acid tablets compared to placebo for treating people with prediabetes
GermanyStudy of Dapagliflozin for Reducing Cardiovascular Events in Adults with High Blood Pressure
AustriaComparing mirikizumab versus azathioprine with glucocorticoids in newly diagnosed patients with moderate-to-severe ulcerative colitis
GermanyStudy on Hydrocortisone for Patients Undergoing Pancreatic Surgery
GermanyStudy comparing prophylactic versus selective surfactant (poractant alfa, phospholipid fraction) administration in preterm infants with respiratory distress syndrome aged 25-30 weeks
GermanyStudy on Low-Dose Aldesleukin for Patients with Pemphigus, Mucous Membrane Pemphigoid, Polymyositis, Dermatomyositis, and Primary Sclerosing Cholangitis
GermanyStudy of controlled-release nicotinamide (CICR-NAM) tablets for treating mild to moderate ulcerative colitis
GermanyStudy of blinatumomab plus drug combination in children and adolescents with acute lymphoblastic leukemia
GermanyStudy on Improving Quality of Life in Cancer Patients Using Dronabinol and Cannabidiol
GermanyStudy on Improving Treatment for Children and Adolescents with Acute Lymphoblastic Leukemia Using Bortezomib, Blinatumomab, and a Drug Combination
AustriaStudy on Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Low-Risk Multiple Myeloma
GermanyIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
